## Barclay Pearce Capital | Research

23 September 2020



Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.au

## **Kathmandu Holdings Ltd**

## Retail

### **BUY**

### KMD A\$1.18 TARGET PRICE A\$1.47

Kathmandu Holdings Limited (KMD) is engaged in the design, marketing and retailing of clothing and equipment for travel and adventure. Currently, KMD 167 stores also operate an online store. KMD's product offering generally falls into two retailing statistical categories: apparel retailing and recreational goods retailing. Apparel goods include technical wear, down jackets, thermals, fleece, woven casual wear and merino for men, women and kids.

Company Data

Company Data	
Number of shares	709.0M
Market Capitalisation	\$833.1M
Free float (%)	87.7
12-month high/low	\$2.47/\$0.47
Average Daily Turnover (\$m)	2.33
% S&P/ASX200	0.05%
DDM Ranking	217
% All Ordinaries	0.04%
GICS Industry Group	Retail
Source: FactSet, Barclay Pearce Capital	

### **Earnings Summary (AUD)**


Year end December	2020A	2021F	2022F	
Revenue (\$M)	752.6	831.3	932.3	
EBITDA (\$M)	78.3	99.9	112.0	
Reported NPAT (\$M)	8.4	49.1	71.2	
Adjusted NPAT (\$M)	29.6	46.3	69.6	
Reported EPS (¢)	1.8	5.9	8.7	
Adjusted EPS (¢ - FD)	6.4	6.1	9.7	
Adjusted EPS growth (%)	-57.6	-3.6	57.6	
Adjusted P/E (x)	18.4	19.1	12.1	
Dividend (¢/sh)	0.0	2.1	5.5	
Gross yield (%)	0.0	2.6	6.6	
Net yield (%)	0.0	1.8	4.6	

Source: Barclay Pearce Capital

Barclay Pearce Capital contributes all company estimates to Thomson

Reuters, FactSet and Capital IQ.

### Share price performance



## Acceleration in Online Sales in FY20 Results

On 23 September Kathmandu Holdings (KMD) announced their FY20 results with the following highlights.

- Acceleration in online sales, with group online sales up 63% to \$106.4 million, now comprising 15.7% of direct to consumer sales
  - Rip Curl online sales up 52% to \$25.5 million; 10.6% of DTC sales
  - Kathmandu online sales up 67% to \$80.9 million; 18.5% of DTC sales
- Group sales up 48.7% to \$801.5 million, including 9 months of Rip Curl
- Statutory NPAT of \$8.9 million includes \$18.0 million of one-off transaction costs, \$4.6 million of restructuring costs and a \$2.6 million impact from the implementation of the IFRS 16 leasing standard;
- Group Underlying EBITDA down 15.3% to \$83.4m;
- Group Underlying NPAT down 44.5% to \$31.5m;
- Operating cash flow up 50.9% to \$93.1m;
- \$207 million capital raise provided balance sheet strength and optionality for future growth, with closing net debt of \$9.4m;

### **COVID-19 Impacts**

- COVID-19 impact estimated at c. \$135 million of sales (\$80 million retail and \$55 million wholesale)
- Full global retail store network closures during initial Lockdowns
- During July, Melbourne stores continued to trade, but with impacted footfall due to a second wave
- Reduced demand for Kathmandu and Rip Curl travel-related products due to border restrictions
- Dividend suspended. No interim dividend paid, and no final FY20 dividend declared

### Outlook

- COVID-19 has continued to impact some key markets at the start
  of FY21 with Melbourne, Auckland, Hawaii, Bali and airport store
  closures. Given post-lockdown retail store performance in FY20,
  we expect demand to return in these markets when stores reopen
- As a result of the COVID-19 disruption, the Group has experienced mixed same store sales performance over the first seven weeks of FY21
- Wholesale order books for both Rip Curl and Oboz are improving for 2H FY21

## **Earnings changes**

KMD's announced FY20 results that were in line with market expectations. But, we are concerned about KMD's first seven weeks of trading in FY21. However, at this stage we don't expect any significant earnings revisions.

We are initiating cover on KMD with a 12-month price target of \$1.47 and with a BUY recommendation. The price target is underpinned by our DDM valuation.

## Barclay Pearce Capital | Research



23 September 2020

Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.au

This Research Report has been prepared by Russell Wright ("Mr Wright") in his capacity as a Corporate Authorised Representative (CAR: 422117) and issued (in Australia) by Barclay Pearce Capital Pty Ltd (ACN 634 843 735) (AFS Licence No. 503 261) ("Barclay Pearce Capital") and remains the property of Barclay Pearce Capital Pty Ltd. No material contained in this Research may be reproduced or distributed, except as allowed by the Copyright Act, without the prior written approval of Barclay Pearce Capital. This Research Report is subject to the disclosures and restrictions set out below.

### **Analyst Certification**

The research analyst(s) identified on the cover of this report individually certify that in respect of each security or issuer that the research analyst covers that: this report accurately reflects his or her personal views about any and all of the subject issuer(s) or securities; and no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or views expressed by the research analyst(s) in this report.

Barclay Pearce Capital provides research services to its client. Mr Wright is General Manager of Research and has over twenty (26) years' experience in the financial services industry, particularly in financial analysis and research report writing. Mr Wright joined the Barclay Pearce team in 2017 where he has been involved in the research and publication of reports. Prior to this Mr Wright worked at a number of entities where he held Director/Head of Research and General Manager of Research positions. Mr Wright holds a Bachelor of Mathematics (Honours) from Edinburgh University and has completed the SDIA Accreditation Program (RG146) through DeakinPrime.

#### **General Disclosure**

Barclay Pearce Capital and its associates (as defined in Chapter 1 of the Corporations Act 2001), officers, directors, employees and agents, from time to time, may own or have positions in securities of the company(ies) covered in this report and may trade in the securities mentioned either as principal or agent or may be materially interested in such securities.

Barclay Pearce Capital does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Barclay Pearce Capital provides research on all ASX200 stocks as well as on other sectors (i.e. artificial intelligence, crypto currencies, food, healthcare, marijuana, mining, payment platforms and technologies) and/or entities which Barclay Pearce Capital considers to be of interest to both Barclay Pearce Capital's clients and the broader financial markets.

#### **Disclaimer & Warning**

This report may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This report does not purport to contain all the information that a prospective investor may require. Before making an investment or trading decision, the recipient must consider market developments subsequent to the date of this document, and whether the advice is appropriate in light of his or her financial circumstances or seek further advice on its appropriateness or should form his/her own independent view given the person's investment objectives, financial situation and particular needs regarding any securities or Financial Products mentioned herein. Information in this document has been obtained from sources believed to be true but neither Barclay Pearce Capital nor its associates make any recommendation or warranty concerning the Financial Products or the accuracy, or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. This document is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any Financial Product, and neither this document or anything in it shall form the basis of any contract or commitment. Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Barclay Pearce Capital, its associates, officers, directors, employees and agents. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

Analysts' Compensation: The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of the analyst(s) research, client evaluation feedback, independent survey rankings and overall firm revenues, which include revenues from, among other business units and corporate finance.

Other International Investors: International investors outside the US, UK, UAE or Canada are encouraged to contact their local regulatory authorities to determine whether any restrictions apply to their ability to purchase this investment and should seek their own advice

Recipient Representations/Warranties: By accepting this report, the recipient represents and warrants that he or she is entitled to receive such report in accordance with the restrictions set out in this document and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of law.

### **Meanings of Barclay Pearce Capital Stock Ratings**

**Buy** – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of 15% or more within a 12-month period. **Hold** – Describes stocks that are neither a buy nor underperform.

**Underperform** – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of less than minus 10% within a 12-month period.

**NR** – The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Barclay Pearce Capital policies.

**Speculative Buy** – Describes stocks we research with a positive bias, whose company fundamentals and/or financials are being covered, but for which there is insufficient information for Barclay Pearce Capital to assign a Buy or Underperform rating.

Free Float (float / current shares outstanding) \*100 – This float figure is the number of shares that are available to the public and is calculated by subtracting the shares held by insiders and those deemed to be stagnant shareholders. Stagnant holders include ESOP's, ESOT's, QUEST's, employee benefit trusts, founding shareholder equity stake plus senior management equity stake, corporations not actively managing money, venture capital companies and shares held by Governments.

Barclay Pearce Capital ACN 634 843 735 AFSL 503

Sydney Office: Level 17, 115 Pitt Street, Sydney NSW 2000 Australia Tel: (61) 2 8288 6900

Website: www.barclaypearce.com.au

# Barclay Pearce Capital | Research



23 September 2020

Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.au

#### **Valuation Methodology**

Barclay Pearce Capital's methodology for assigning stock and credit ratings may include the following: market capitalisation, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of peer comparisons, market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of parts, net asset value, discounted dividend model (DDM), franking credits and return on equity (ROE) over the next 12 months.

### **Conflicts of Interest**

Barclay Pearce Capital does not have any material interests in the financial product discussed in this Research Report nor will it receive any benefits in relation to the publication of this Research Report. Barclay Pearce Capital manages all Conflicts of Interest in accordance with its Conflicts of Interest Policy. Please contact us if you require any further information.

Sydney Office: Level 17, 115 Pitt Street, Sydney NSW 2000 Australia Tel: (61) 2 8288 6900

Website: www.barclaypearce.com.au